Ioanna
Ioanna Chinou, Pagagou GR
Patent application number | Description | Published |
---|---|---|
20110034427 | Anti-aging properties of quercetin, 18alpha-glycyrrhetinic acid and hederagenin and their derivatives - Quercetin, 18 α-glycyrrhetinic and/or hederagenin and/or their derivatives are used as anti-aging and/or whitening agents for the topical treatment of skin. Methods for testing the anti-aging and whitening properties of these compounds are disclosed. | 02-10-2011 |
Ioanna Doimas, Vrilissia GR
Patent application number | Description | Published |
---|---|---|
20150345266 | METHOD AND APPARATUS FOR TREATING A SUBTERRANEAN REGION - A method for treating a subterranean region includes running a tubular string including a plurality of sealed fluid ports distributed along its length through an upper lined wellbore section and into a lower drilled bore section which intercepts a subterranean region, wherein the lower drilled bore section includes a first fluid. A second fluid is delivered through one of the tubular string and an annulus defined between the tubular string and a wall of the bore to displace the first fluid from the annulus, wherein fluid communication between the tubular member and the annulus is provided via a displacement port in a lower end region of the tubular string. At least one of the sealed fluid ports may subsequently be opened and a treating fluid is delivered through the tubular string and into the annulus via the at least one opened fluid port to treat the subterranean region. | 12-03-2015 |
Ioanna Eleftheriadou, London GB
Patent application number | Description | Published |
---|---|---|
20160101174 | LENTIVIRAL VECTORS WITH TROPISM TO MOTOR NEURONS COMPRISING AN ANTIBODY THAT BINDS TO A PRE-SYNAPTIC TERMINAL RECEPTOR ON THE NEUROMUSCULAR JUNCTION AND A FUSOGENIC PROTEIN - The present invention relates to vectors useful in the treatment of disease through targeted delivery. In particular, the present invention relates to vectors useful in the treatment of disease associated with neuronal degeneration, such as amyotrophic lateral sclerosis (ALS) and spinal muscular atrophy (SMA). | 04-14-2016 |
Ioanna Georgopoulou, Thessaloniki GR
Patent application number | Description | Published |
---|---|---|
20100094055 | PROCESS FOR THE PREPARATION OF PHENETHYLAMINE DERIVATIVES - The present invention relates to an improved process for the preparation of essentially pure Venlafaxine Hydrochloride. Particularly, the process for the preparation of Venlafaxine Hydrochloride comprises the following steps: i) Preparation of 1-[Cyano-1-(4-methoxyphenyl)methyl]cyclohexanol, ii) Preparation of crude Venlafaxine Hydrochloride by reduction of 1-[Cyano-1-(4-methoxyphenyl)methyl]cyclohexanol with Alkali metal borohydride and Lewis acid and subsequent conversion to Venalfaxine hydrochloride with formic acid and paraformaldehyde and finally iii) Purification of crude Venlafaxine Hydrochloride. | 04-15-2010 |
20120253051 | PROCESS FOR THE PREPARATION OF ROPINIROLE AND SALTS THEREOF - The present invention relates to an improved process for the preparation of Ropinirole and pharmaceutical acceptable salts or derivatives thereof, in particular to a process for large scale production of Ropinirole and salts thereof in high yield and high purity and pharmaceutical preparations containing said compounds. | 10-04-2012 |
20120253074 | PROCESS FOR THE PREPARATION OF O-DESMETHYL-VENLAFAXINE AND SALTS THEREOF - The present invention relates to a novel process for the preparation of O-desmethyl venlafaxine (ODV) and the pharmaceutically acceptable salts thereof, wherein it comprises (i) provision of spiro-venlafaxine compound as intermediate; (ii) conversion of spiro-venlafaxine intermediate into ODV free base in a one-pot process; and (iii) optionally conversion ODV free base into pharmaceutically acceptable salts. The present invention further relates to novel processes for the preparation of crystalline salts of OD V-succinate and ODV-oxalate. | 10-04-2012 |
Ioanna Kontiza, Pallini Attikis GR
Patent application number | Description | Published |
---|---|---|
20150080385 | OPHTHALMIC PHARMACEUTICAL COMPOSITION CONTAINING A CARBONIC ANHYDRASE INHIBITOR AND METHOD FOR THE PREPARATION THEREOF - The present invention relates to a stable pharmaceutical formulation for topical administration containing a therapeutically effective quantity of Brinzolamide or ophthalmologic acceptable salts thereof and an effective quantity of a surfactant such as poloxamer, to be used for the treatment of ocular hypertension and glaucoma. | 03-19-2015 |
Ioanna Koutri, Pallini Attikis GR
Patent application number | Description | Published |
---|---|---|
20100297225 | SUSTAINED-RELEASE PHARMACEUTICAL FORMULATION CONTAINING AN ANTIMUSCARINIC AGENT AND A WETTING AGENT AS WELL AS A PROCESS FOR THE PREPARATION THEREOF - The present invention relates to improved sustained release dosage forms such as tablets and capsules, and in particular to a pharmaceutical formulation for oral administration comprising a therapeutically effective quantity of an antimuscarinic agent, such as Tolterodine or pharmaceutical acceptable salt, derivative, prodrug and metabolite thereof in combination with a wetting agent, such as Sodium Docusate to improve the release of the active ingredient and a method for the preparation thereof. | 11-25-2010 |
20110033538 | Pharmaceutical composition containing a pyrrolidone anticonvulsant agent and method for the preparation thereof - The present invention relates to a pharmaceutical formulation of solid dosage forms comprising a therapeutically effective amount of a pyrrolidone anticonvulsant agent, and in particular Levetiracetam or a pharmaceutical acceptable salt or derivative thereof, in combination with an effective diluent, such as Dibasic Calcium Phosphate, and additional pharmaceutical excipients, and a process for the preparation thereof by wet granulation. | 02-10-2011 |
20140187520 | STABLE INJECTABLE PHARMACEUTICAL COMPOSITION OF VITAMIN D RECEPTOR AGONIST AND PROCESS FOR PREPARATION THEREOF - The present invention relates to a stable pharmaceutical composition for intravenous administration comprising a Vitamin D receptor agonist, particularly paricalcitol, and a process of preparation thereof. | 07-03-2014 |
20150080385 | OPHTHALMIC PHARMACEUTICAL COMPOSITION CONTAINING A CARBONIC ANHYDRASE INHIBITOR AND METHOD FOR THE PREPARATION THEREOF - The present invention relates to a stable pharmaceutical formulation for topical administration containing a therapeutically effective quantity of Brinzolamide or ophthalmologic acceptable salts thereof and an effective quantity of a surfactant such as poloxamer, to be used for the treatment of ocular hypertension and glaucoma. | 03-19-2015 |
Ioanna Mylonaki, Genève CH
Patent application number | Description | Published |
---|---|---|
20160045450 | PHARMACEUTICAL FORMULATION FOR USE IN THE TREATMENT AND/OR PREVENTION OF RESTENOSIS - The present invention relates generally to a pharmaceutical formulation for use in the treatment and/or prevention of restenosis in a subject in need thereof. Methods of treatment and/or prevention are also provided. | 02-18-2016 |
Ioanna Ntai, Evanston, IL US
Patent application number | Description | Published |
---|---|---|
20150175998 | Methods and Kits to Create Protein Substrate.about.HECT-Ubiquitin Ligase Pairs - Methods and kits to use in the isolation and identification of crosslinked protein substrate ubiquitin ligase complexes are disclosed. More specifically the methods and kits disclosed herein describe the use of bifunctional thiol-and-amine crosslinkers to covalently bind an endogenous or exogenous HECT-ubiquitin ligase to a downstream protein substrate, preferably in a cell lysate. | 06-25-2015 |
Ioanna Pappa, Stockholm SE
Patent application number | Description | Published |
---|---|---|
20120215503 | ARRANGEMENT AND METHOD RELATING TO ANALYSIS OF TRANSMISSION LINES - Embodiments of the present invention relate to an arrangement for analyzing transmission line properties. Measurement data providing means provide data of a first frequency dependent line property, line property calculation arrangement with model handling means, a Hubert transform handler and line property determination means calculate said first property based on model parameters, line resistance at 0 frequency, roc r cut-off frequency, v, line capacitance C∞r and line inductance Σ̂. The line model handling means calculates the line inductance L(J) via a Hubert transform of Q(f/v)r relating line resistance R(J) to roc such as formula (I). The Hilbert transform values are calculated using a parameterized closed form expression for the Hubert transform or they are tabulated. The line property determination means calculates the first property and criteria function application means uses the measured first property and the calculated first property for model parameters to find optimized numerical model parameter values. | 08-23-2012 |
20150373710 | Residential Local Break Out in a Communication System - Method and residential control node ( | 12-24-2015 |
Ioanna Skountzou, Atlanta, GA US
Patent application number | Description | Published |
---|---|---|
20100330190 | IMMUNOGENIC COMPOSITIONS AND METHODS OF USE THEREOF - Embodiments of the disclosure encompass compositions and methods for generating immune responses in an animal or human host. Embodiments of the compositions encompass proteins derived from the surface proteins of bacteria and protozoa, and in particular the flagellum component flagellin, and which have adjunctival properties when administered in conjunction with an immunogen. Embodiments of the compositions of the disclosure are modified to incorporate a heterologous transmembrane-cytoplasmic domain allowing the peptides to be incorporated into virus-like particles. Embodiments of the methods of generating an immunological response in an animal or human comprise exposing the immune system of an animal or human host to an immunogen and a virus-like particle comprising an adjuvant polypeptide including a host cell Toll-like receptor ligand polypeptide having a transmembrane-cytoplasmic tail polypeptide, and a heterologous signal peptide. | 12-30-2010 |
20150183837 | IMMUNOGENIC COMPOSITIONS AND METHODS OF USE THEREOF - Embodiments of the disclosure encompass compositions and methods for generating immune responses in an animal or human host. Embodiments of the compositions encompass proteins derived from the surface proteins of bacteria and protozoa, and in particular the flagellum component flagellin, and which have adjunctival properties when administered in conjunction with an immunogen. Embodiments of the compositions of the disclosure are modified to incorporate a heterologous transmembrane-cytoplasmic domain allowing the peptides to be incorporated into virus-like particles. Embodiments of the methods of generating an immunological response in an animal or human comprise exposing the immune system of an animal or human host to an immunogen and a virus-like particle comprising an adjuvant polypeptide including a host cell Toll-like receptor ligand polypeptide having a transmembrane-cytoplasmic tail polypeptide, and a heterologous signal peptide. | 07-02-2015 |
Ioanna Stamati, London GB
Patent application number | Description | Published |
---|---|---|
20120070377 | COMPOUNDS AND BIOLOGICAL MATERIALS AND USES THEREOF - The invention provides compounds of Formula (I): wherein b, D, R | 03-22-2012 |
20150133653 | COMPOUNDS AND BIOLOGICAL MATERIALS AND USES THEREOF - The invention provides compounds of Formula I: | 05-14-2015 |
Ioanna Stergiades, San Francisco, CA US
Patent application number | Description | Published |
---|---|---|
20090023777 | Substituted 4-amino-benzylpiperidine compounds - This invention provides 4-amino-1-benzylpiperidine and related compounds and pharmaceutically acceptable salts thereof which are useful as muscarinic receptor antagonists. This invention also provides pharmaceutical compositions containing such compounds; processes and intermediates useful for preparing such compounds; and methods for treating disease conditions mediated by muscarinic receptors, such as overactive bladder, irritable bowel syndrome, asthma and chronic obstructive pulmonary disease, using such compounds. | 01-22-2009 |
20100125150 | CRYSTALLINE FORM OF A BETA2 ADRENERGIC RECEPTOR AGONIST - The invention provides a novel β | 05-20-2010 |